HIKMA’S EYEING A REINVENTION (BUY; 22% UPSIDE)
12/01/22 -" Unlike Smaller Pharmas’ lackluster performance (up 16% since the March 2020 lows vs. 73% gain for STOXX600) since the COVID-19 outbreak, Hikma (Buy, UK) – a generics manufacturer, leveraging market ..."
Pages
55
Language
English
Published on
12/01/22
You may also be interested by these reports :
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...